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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
sertraline is effective at reducing the symptoms of anxiety in those diagnosed with generalized
anxiety disorder (GAD).
STUDY DESIGN: This is a systematic review of three randomized control trials (RCTs)
published between 2008 and 2015, all in the English language and published in peer-reviewed
journals.
DATA SOURCES: Three randomized control trials that study the effects of sertraline for
reduction of anxiety symptoms in patients with GAD, obtained using PubMed, CINAHL Plus
and Academic Search Premier.
OUTCOMES MEASURED: The primary outcome measured in each study was patient-reported
reduction in anxiety symptoms and improvement of quality of life. These outcomes were
measured using several scales, including the Hamilton Rating Scale for Anxiety, the Pediatric
Anxiety Rating Scale, the Children’s Global Assessment Scale, The Clinical Global ImpressionImprovement Scale, and the Clinical Global Impressions Severity Scale.
RESULTS: Cvjetkovic-Bosnjak et al. found sertraline to be equally effective as pregabalin for
the treatment of GAD (Eur Rev Med Pharmacol Sci 2015: 19 (11), 2020-2024). Similarly,
Mokhber et al. found sertraline to be equally effective to buspirone in treating GAD
(Psychiatry Clin Neurosci: 64: 128-133. doi: 10.1111/j.1440-1819.2009.02055.x). Finally,
Walkup et al. found that sertraline and cognitive behavioral therapy either in combination
or as monotherapies are effective in treating GAD (NEJM 2008; 359 (26): 2753-2766. doi:
10.1056/NEJMoa0804633).
CONCLUSION: The results of this systematic review show that sertraline is effective in treating
the symptoms of anxiety in patients with a diagnosis of generalized anxiety disorder. While the
results from these studies were promising, additional research with larger, more diverse
populations, standardized measurements of outcomes, increased time frame, and further
examination of adverse drug reactions and cost-effectiveness are required to determine the true
long-term benefit of sertraline as therapy for GAD.
KEY WORDS: sertraline, generalized anxiety disorder.
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INTRODUCTION
Generalized anxiety disorder (GAD) is a chronic mental illness with a prevalence of 57% in the general population.1 While the exact etiology of this illness is unknown, it is likely
multifactorial, and has been linked to disrupted functional connectivity of the amygdala and its
processing of fear. In addition to constant worry, the physiological effects of anxiety may include
headache, paresthesias, fasciculations, vertigo, syncope, abdominal pain, nausea, vomiting or
diarrhea, indigestion, dry mouth, shortness of breath, tachycardia, chest pain, palpitations,
frequent urination, perspiration or excessive fatigue.3 GAD leads to functional impairment and
significantly reduced patient’s quality of life.1
The economic burden of anxiety on the healthcare system is tremendous and cannot be
ignored. Though there is not an exact estimate within the past few years, between 2009 and 2011
there were an estimated 1,247,000 ED visits for anxiety annually, representing 0.93% of all ED
visits in the United States.4 Additionally, it is estimated that between 2009 and 2010, the annual
overall direct medical costs associated with anxiety disorders in the US was $1657.52 per person,
or $33.71 billion in total.5
Many different methods have been used to treat GAD. According to the guidelines of the
World Federation of Societies of Biological Psychiatry, first-line treatments for GAD are
selective serotonin reuptake inhibitors (SSRIs), selective serotonin and norepinephrine reuptake
inhibitors (SNRIs), and pregabalin, an atypical anxiolytic.1 Long-acting benzodiazepines such as
diazepam are also recommended for the treatment of anxiety.6 Psychotherapy like CBT is
recommended mostly in combination with pharmacotherapy.1 Despite the many options already
available, few patients with GAD receive adequate treatment. In fact, according to a 2009
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national representative survey of 3,032 respondents in the United States, guideline-concordant
care was received by only 32.5% of people with GAD in the primary care sector.7
While the aforementioned methods of treatment have had efficacy in treating anxiety,
they are not without drawbacks. For example, Gale and Millichamp found that various drug
treatments, such as benzodiazepines, buspirone, hydroxyzine, antidepressants,
and pregabalin may all reduce symptoms of anxiety in people with GAD, but they can have
unpleasant adverse effects, and most trials have been short term.8 Additionally, Gale and
Millichamp found that benzodiazepines, while effective, increase the risk of dependence,
sedation, and accidents, and can be harmful to neonates if used during pregnancy.8 Furthermore,
buspirone may be less effective in patients who have recently taken benzodiazepines.8
Sertraline is an SSRI that is already commonly used to treat other anxiety disorders. For
example, treatment of panic disorder with sertraline results in a decrease in the number of panic
attacks and an improved quality of life.9 Additionally, sertraline is effective for the treatment of
social phobia.10 Though sertraline is generally not a first-line drug for the treatment of GAD, it
may have benefits for patients with this condition as well, given its already-proven efficacy with
other anxiety disorders. In this systematic review, the effectiveness of sertraline at reducing
symptoms of anxiety in those diagnosed with GAD will be evaluated through three randomized
control trials.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not sertraline is
effective at reducing symptoms of anxiety in those diagnosed with generalized anxiety disorder.
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METHODS
The population studied in this systematic review was obtained from three randomized
control trials that included patients suffering from symptoms of anxiety with a clinical diagnosis
of GAD. Oral sertraline was the intervention studied in comparison with other methods of
treating anxiety including pharmacologic therapy with buspirone and pregabalin, CBT and
combination therapy. The key words employed in the author’s search for sources via PubMed,
CINAHL Plus and Academic Search Premier included “sertraline” and “generalized anxiety.”
All articles chosen for this systematic review include outcomes that are patient-oriented
(POEMs) and are relevant to the author’s clinical question. Articles selected fit the inclusion
criteria of randomized control trials published after 2008 with no other systematic review, metaanalysis or articles published in the Cochrane database regarding the same clinical question.
Studies were excluded if they were published before 2008 and not of a primary research design.
Key statistics include p-values, confidence intervals, mean change from baseline and standard
deviation. Additional relevant statistics reported included numbers needed to treat (NNT),
experimental event rate (EER), control event rate (CER), absolute risk reduction (ARR), relative
risk (RR) and relative benefit increased (RBI).
Table 1: Demographics and Characteristics of Included Studies
Study

Type

#
Pts.

Age
(yrs.)

Inclusion
Criteria

Exclusion Criteria

W/D

Interventions

Cvjetjovic
-Bosnjak1
(2015)

Double
Blind
RCT

107

20-60

Any male or
female
patient aged
20-60 with a
diagnosis of
GAD and an
HAMA total
score >20

Pts. w/ comorbid mental
disorders (depression,
alcoholism, personality
disorders, psychotic
disorders or somatic
dysfunction (DM, HTN,
cardiomyopathy, thyroid
dysfunction).

0

Mokhber11
(2010)

Single
Blind
RCT

46

>60

Any male or
female with
a DSM-IV

Patients w/ severe
depressive symptoms or
grief reaction in the past

0

Sertraline with
a mean dose of
150 mg/day x 4
weeks
vs. Pregabalan
with a mean
dose of 225
mg/day x 4
weeks.
Oral sertraline
50-100 mg/day
x 8 weeks
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diagnosis of
GAD, age
>60, HRSA
score >/= 20
and GDS
severity
score </=10

Walkup12
(2008)

DoubleBlind
RCT

488

7-17

Children
between the
ages of 7
and 17 years
with a
primary
diagnosis of
separation
anxiety,
GAD or
social
phobia

6 months; patients w/
any clinically important
medical disease or
abnormality on PE (e.g.
head trauma, thyroid
issues, acute heart
disease); pts. w/ other
Axis I psychiatric
disorders or cognitive
disturbances; pts. who
used other drugs with
psychotropic effects
within 4 weeks prior to
the study.
Children w/ unstable
medical conditions or
who were refusing to
attend school due to
anxiety or were
unresponsive to two
trials of SSRIs; sexually
active/ pregnant females
not using birth control;
children receiving
psychoactive
medications other than
stable doses of
stimulants w/ psychiatric
diagnoses; children who
were an acute risk to
themselves or others.

increased
gradually
according to a
fixed
incremental
schedule vs.
Buspirone 1015 mg/day x 8
weeks.

46

Sertraline
administered
on a fixedflexible
schedule
beginning with
25 mg/day and
adjusted up to
200 mg/day by
week 8 vs. 8
weeks of CBT
alone vs. 8
weeks of
CBT/Sertraline
combined.

OUTCOMES MEASURED
In this review, three RCTs were employed, two double blinded and one single blinded,
with the measured outcomes being patient oriented evidence that matters (POEMs). The primary
POEM measured in this review was reduction in symptoms of anxiety. This was ascertained
using interviews with patients and several different scales. Cvjetkovic et al1 and Mokhber et al11
used the Hamilton Rating Scale for Anxiety (HRSA). Walkup et al12 used four different scales,
including the Clinical Global Impression-Improvement Scale, the Pediatric Anxiety Rating
Scale, the Clinical Global Impressions Severity Scale, and the Children’s Global Assessment
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Scale. Data was statistically measured via the patient’s self-reported reduction in anxiety
symptoms using the above scales and reported either in terms of whether or not patients
responded positively to treatment or as a change in means over the course of the study, using pvalues and confidence intervals to determine the clinical significance of the data.
RESULTS
To determine if the effect of sertraline on anxiety symptoms was advantageous the
three articles being evaluated used p-values. Cvjetkovic1 claimed statistical significance if the pvalue was <0.05. Mokhber11 and Walkup12 claimed statistical significance with a p-value of
<0.01. In Cvjetkovic-Bosnjak et al1 107 patients aged 20-60 at an outpatient psychiatric clinic
were randomly assigned to 4 weeks of treatment with pregabalin or sertraline. A mean daily dose
of 150 mg of sertraline and a mean daily dose of 225 mg of pregabalin was given.1 Patients
attended weekly visits with two different psychiatrists to assess the severity of their anxiety
symptoms, and at the end of the four week regimen, the final effectiveness and side effects
assessments were made by the same psychiatrist that did the baseline evaluations.1 patients
treated with sertraline had a 10.1-point reduction in their overall HRSA score after 4 weeks1
(Table 2). Additionally, 96% of patients treated with sertraline showed ratings of very much
improved.1 This study found that the most frequently reported adverse event amongst those
treated with sertraline was nausea (13%), but that the adverse events were short-lasting and of
mild intensity.1
Table 2. Change in Hamilton Anxiety Scale scores in patients with generalized anxiety
disorder treated 4 weeks with sertralineα

α

HRSA Scores
Sertraline
Pregabalan

Baseline
24.00 +1.2
23.60 +2.6

Week 1
23.50 + 0.9
18.10 + 2.2

Week 3
14.70 + 1.0
15.20 + 1.3

Data derived directly from Cvjetkovic-Bosnjak et al1

Week 4
13.90 + 0.2
14.20 + 0.7
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Mokhber et al. studied 46 patients aged >60 with a clinical diagnosis of GAD. There
were 21 patients receiving a daily dose of 50-100 mg of sertraline and 25 patients receiving a
daily dose of 10-15 mg of buspirone, and the dosages were gradually increased according to a
fixed incremental schedule.9 Efficacy of these two medications was assessed by a psychiatrist
blind to the treatment after 2, 4, and 8 weeks.9 In this study, the mean score on the Hamilton
Rating Scale for Anxiety after 8 weeks also significantly decreased in the sertraline group.11 For
the purpose of this review, the focus will remain on week 4 as an endpoint. (Table 3). By week 4,
there was a nearly 25% decrease in HRSA scores for patients treated with sertraline.11 No
clinically significant serious adverse events were observed during the study period, and no one
withdrew from the study.11
Table 3: Mean HRSA scores for patients treated with sertraline and buspirone weeks 0-4α

α

HRSA Scores
Sertraline
Buspirone

Week 0
28.63 +/- 5.19
28.84 +/-5.15

Week 2
28.48 +/- 4.90
18.96 +/- 5.81

Data derived directly from Mokhber et al11

Week 4
21.48 +/- 4.64
15.60 +/- 5.45

Finally, Walkup et al. conducted a two-phase multicenter RCT for 488 children and
adolescents between the ages of 7 and 17 years with a clinical diagnosis of GAD. Phase 1 was a
12-week trial of short-term treatment comparing cognitive behavioral therapy, sertraline, and
their combination with a placebo drug, and phase 2 was a 6 month open extension for patients
who had a response in phase 1. In phase 1, which is the primary focus of this review, CBT
involved fourteen 60 minute sessions, while pharmacotherapy involved 8 sessions of 30-60
minutes each in which subjects rated the severity of their anxiety symptoms.12 Sertraline and a
matching placebo were administered on a fixed-flexible schedule beginning with 25 mg/day and
adjusted up to 200 mg/day by week 8.12 Patients were monitored for a total of 12 weeks via
interviews administered by independent evaluators who were unaware of study group
assignments.10 For the purpose of this review, week 4 will be the endpoint studied. This study
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used several different scales to measure outcomes. The Clinical Global Impression Improvement
Scale demonstrated whether or not patients had a positive response to therapy, with a score from
1-7 in which 1 indicated very much improved and 2 indicated much improved.12 The study found
that the percentages of children with a score < 3 at 4 weeks was 18.8% in the sertraline group,
exceeding those with a response to CBT or placebo in the same time frame12 (Table 4).
Table 4. Patients (%) with response to sertraline, placebo, CBT, and combination therapy
on the Clinical Global Impression-Improvement Scale with score <3 through week 4 α
Clinical Global Impression
Week 4 outcomes
Improvement Scale

% with response to sertraline

18.8

% with response to placebo

6.6

% with response to CBT

9.3

% with response to combination
therapy

21.4

α

Data derived directly from Walkup et al12

Scores on the Pediatric Anxiety Rating Scale range from 0-30, with scores higher than 13
consistent with moderate levels of anxiety and a diagnosis of an anxiety disorder.12 By the end of
4 weeks, there was nearly 25% rate of improvement in the sertraline group12 (Table 5). Scores on
the Clinical Global Impressions Severity Scale and the Children’s Global Assessment Scale
demonstrated similar levels of efficacy for sertraline by week 4.12
Table 5: Change in Pediatric Anxiety Rating Scale in patients treated with 4 weeks of
sertraline or placebo or CBT or combination therapyα
Pediatric Anxiety
Rating Scale
Sertraline

Baseline

Week 4

18.8 +/- 3.9

14.2 +/- 4.0

Placebo

19.6 +/- 3.9

16.0 +/- 4.1

Cognitive
behavioral therapy
Combination
therapy

18.9 +/- 3.9

16.0 +/- 3.9

19.4 +/- 3.9

14.6 +/- 3.9

α

Data derived directly from Walkup et al12
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DISCUSSION
While these studies demonstrate the efficacy of sertraline at reducing symptoms of
anxiety in those with a diagnosis of GAD, they were not without limitations. Cvjetkovic-Bisnjak
et al. was a small single center study with a limited age group and excluded patients with many
comorbidities, limiting the generalizability of the study.1 Mokhber at al. primarily focused on
GAD in the elderly population, and was again limited by its small sample size.9 Additionally, the
association between medical illness, cognitive impairment, depression and GAD in the elderly
excluded several subjects, thus limiting the generalizability of the study.11 Walkup et al.
acknowledged that despite intense outreach, the sample did not include the most
socioeconomically disadvantaged children.12 Additionally, exclusion of children and teens with
major depression and pervasive developmental disorders may have limited the generalizability of
the results to these populations.12
A final limitation of all three studies are the scales used to measure the outcomes. As
noted, several different scales of measurement were used to assess the severity of anxiety
symptoms. While the scales used are helpful in obtaining statistics about the specific populations
studied, a more conclusive result may be obtained if a universal scale was utilized. For example,
the Clinical Useful Anxiety Outcome Scale is one example of a standardized scale that may be
used. A standardized scale will strengthen the validity of future studies on this topic.
In terms of cost, sertraline appears to be an affordable option to treat GAD. In June, 2006,
after the U.S patent for Zoloft expired, sertraline was introduced in generic form worldwide.14
Panzarino and Nash found that among the established SSRIs, drug acquisition costs were lowest
for sertraline and paroxetine, and both are available in extended dosage forms to reduce the need
for multi-tablet therapy.14 Similarly, Ifigenia et al. found sertraline to be the most cost-effective
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drug for patients with GAD.15 While sertraline is often recommended in combination with CBT,
Creswell et al. found that while cognitive behavioral therapy is effective, it is expensive and
trained therapists are scarce.16 In light of this, sertraline may be a more cost-effective method of
solo therapy for GAD for those who do not have access to an affordable and qualified therapist.
More attention should be given to the negative side effects and drug interactions of
sertraline. In October of 2004, the FDA issued a black box warning for sertraline indicating that
the use of the drug in adolescents may increase the risk of suicidal ideations and behaviors.17
Additionally, when compared to other SSRIs, sertraline tends to be associated with a higher rate
of psychiatric side effects and diarrhea.18 If used during pregnancy, sertraline increases risk of
preterm delivery, low birth weight and lower APGAR scores.19 While sertraline may be effective
for treating GAD, the side effects cannot be ignored and should be further examined to determine
if the risks outweigh the benefits of this drug.
CONCLUSION
From these three studies, it can be concluded that sertraline is an effective therapy for
reducing symptoms of anxiety in those diagnosed with GAD. In all three studies, a statistically
significant decrease in symptom severity was achieved in patients who underwent a daily trial of
sertraline. In order to further assess the efficacy of sertraline as solo therapy for GAD, it would
be beneficial to complete further studies with larger and more diverse population. The long-term
safety, tolerability, and efficacy of sertraline should be further investigated, but there is benefit
to short-term use of sertraline for reduction of anxiety symptoms in those with GAD.
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